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ABSTRACT: 
Aim: Long-term administration of lithium has been associated with the development of a 
chronic interstitial fibrosis in addition to nephrogenic diabetes insipidus (NDI).  Earlier 
studies have demonstrated that amiloride, by blocking the epithelial sodium channel ENaC 
and thus preventing lithium uptake into the principal cells of the collecting ducts, can 
partially reverse lithium-induced NDI.  However, there are no long-term studies examining 
whether or not amiloride also modifies the progressive chronic interstitial fibrosis and 
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Methods:  Using an established animal model of lithium-induced chronic interstitial fibrosis, 
rats were treated with amiloride and lithium for 5 months following one month of exposure 
to lithium alone and compared with control animals and those given only lithium. 
Results and Conclusions:  In this study, the 5 months of amiloride therapy partially mitigated 
the lithium-induced NDI and limited the further progression of lithium-induced kidney 
fibrosis.  This improvement was associated with decreased expression of the pro-fibrotic 
connective tissue growth factor (CTGF), along with reduced myofibroblast infiltration and 
decreased collagen deposition around the distended cortical collecting ducts.  This may, in 
part, be mediated by modifying lithium-induced alterations in  β-catenin activity through its 
effects on GSK-3β. 
 
KEY WORDS: Lithium, amiloride, chronic interstitial fibrosis. 
 
Lithium is a widely used and effective therapy to treat individuals with mood disorders. 
However, lithium therapy has well documented side effects on the kidney, most obviously 
the development of nephrogenic diabetes insipidus (NDI).1 Additionally, long term 
medication with lithium has been associated with the development of a chronic focal 
interstitial fibrosis, tubular atrophy and focal glomerulosclerosis2 that may progress to end 
stage kidney disease.3  A chronic, 6 months, rat model of lithium-induced renal fibrosis, with 
minimal active inflammation, which mimics the chronic kidney interstitial fibrosis seen in the 
human kidney, has been previously described.4  This was characterised by cystic dilatation of 
the cortical collecting ducts, a progressive interstitial fibrosis, with increasing numbers of 
myofibroblasts, enhanced transforming growth factor-β1 (TGF-β1) expression, interstitial 
collagen deposition and a minimal inflammatory cellular response.  The earliest changes 
were evident at 1 month and progressed over the subsequent 5 months.  It has been 
suggested that further mechanistic validation of this model may make lithium a very useful 
tool for the study of pathogenesis of chronic interstitial fibrosis with minimal impact on 
renal function.5 
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 The main action of lithium appears to be on the principal cells of the collecting duct, 
which has been well described by numerous authors, and which leads to NDI.1,6,7  Lithium 
enters these cells via the epithelial sodium channel ENaC, situated on the apical (luminal) 
membranes.8,9 .  Within the principal cells, the initial effect of lithium is to inhibit arginine 
vasopressin stimulated aquaporin-2 (AQP2) translocation to, and its insertion into, the apical 
cell membrane.  Longer term, lithium also down-regulates AQP2 synthesis.6 The lack of 
AQP2 creates a barrier to  the passive movement of water down its osmotic gradient, 
leading to the excretion of a large volume of dilute urine, manifest as NDI.  Amiloride acts to 
block lithium uptake through ENaC.8,9 The relatively short term administration of amiloride 
has been shown to partially correct the lithium-induced NDI in both animal and human 
studies.10,11  However, to date there are no long term studies examining whether or not 
partial correction of the lithium-induced NDI with amiloride modifies the progressive 
chronic interstitial fibrosis, tubular atrophy  and glomerular sclerosis  often evident with 
long-term lithium exposure.  In a clinical setting, amiloride administration is not usually 
commenced at the time of initiation of lithium therapy, rather only if the lithium-induced 
NDI becomes a clinical problem.  Therefore, using our rat model of chronic lithium 
exposure,4 amiloride treatment was commenced after the establishment of lithium-induced 
NDI, in order to reflect usual clinical practice.  In this study, 5 months of lithium therapy is 
shown to partially correct the lithium-induced NDI and limit the further progression of 
lithium-induced kidney fibrosis.  This improvement was associated with decreased 
expression of the profibrotic cytokine connective tissue growth factor (CTGF), along with 
reduced myofibroblast infiltration and decreased collagen deposition around the distended 
cortical collecting ducts. 
METHODS 
Animals and protocols 
Wistar male rats (200 g) from the Hercus-Taieri Resource Unit, University of Otago were 
separated into 3 groups, each of 6 rats (i) a control group, (ii) a lithium group, and (iii) an 
amiloride group.  Ethical approval for the protocols described here was given by the 
University of Otago Animal Ethics Committee (92/08), under New Zealand National Animal 
Welfare guidelines. 
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 To induce NDI and subsequent chronic interstitial fibrosis, the protocol of Kwon et 
al.12 was extended.4 The control group was kept for 6 months on a standard rodent diet 
(Speciality Foods, Perth, Australia) and given tap water ad libitum.  Both experimental 
groups received tap water and the same standard rodent diet with the addition of 40 mmol 
lithium/kg dry food (as lithium carbonate) for the first 7 days, followed by 60 mmol 
lithium/kg dry food (lithium diet) for the rest of the experimental period.  To enable 
adequate mixing of the diet with the lithium, all food pellets were pulverised to a fine 
powder in a blender.  There was no difference in weight gain between control rats fed 
whole or powdered pellets.  It has been well established that this protocol results in plasma 
lithium levels comparable to the therapeutic levels in human plasma (0.8-1.3 mmol/l) and 
minimises the reduced weight gain that can be caused by lithium.  The  amiloride group was 
given the same diet as the rats in the lithium group but after 1 month their drinking water 
was supplemented with 0.2 mmol/l amiloride.10  The NDI caused by lithium can lead to 
dehydration, salt wasting and lithium intoxication. Consequently, all rats administered 
lithium were given access to a salt block. Body weight was measured weekly and water 
intake daily. 
 To verify previously examined physiological and morphological changes after 1 
month exposure to lithium,10 a further 4 rats were given a lithium diet as above. All rats 
prior to euthanasia were placed singly in metabolic cages and allowed to settle for 24 hours. 
In the subsequent 24 hours, water uptake (mls) was measured, and urine was collected 
under mineral oil, the volume measured (mls) and then stored at -20oC for later analysis.  
Animals were then narcotised with carbon dioxide, killed by decapitation, and the kidneys 
removed.  The kidneys were sectioned longitudinally: one half was  placed in 10% neutral 
buffered formalin for 4 hours, microwaved to 55oC for 5 minutes, then placed in 70% alcohol 
for immunohistochemistry, and the remaining halves were placed in RNALater® (Ambion, 
Life Technologies, ThermoFisher Scientific, Waltham, MA, USA).  At the time of decapitation, 
blood was collected from the neck, spun immediately, and the plasma decanted and frozen 
for later analysis.  The control, lithium and amiloride groups were maintained for a further 5 
months and then treated similarly. 
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Plasma and urine analysis 
The osmolality of the urine and plasma samples was determined using vapour pressure 
osmometry (Wescor 5500, Logan, UT, USA).  Sodium, potassium and lithium concentrations 
in the urine and plasma of each rat were determined by flame photometry (Radiometer 
FLM3, Bronshoj, Denmark).  Chloride ions in the plasma were measured electrometrically 
using a Cotlove chloride titrator (American Instrument Co., Silver Spring, MD, USA).  
Creatinine concentrations in the plasma were measured spectrophotometrically after 
appropriate dilution (Randox Laboratory, London, UK), and urea was also measured in the 
plasma (Pointe Scientific, Canton, MI, USA) to further assess renal function.  Urinary protein 
was determined using bicinchoninic acid (BCA kit, Pierce Chemical Co., ThermoFisher 
Scientific, Rockford, IL, USA) using bovine serum albumin (BSA) (2mg/ml) as a standard.  
Amiloride was measured in both urine and plasma by Liquid Chromatography/Mass 
Spectrometry (LCMS, Agilent 1200 series LC system with an ABI 3200 QTrap LCMSMS 
(Applied Biosystems Instruments, Rockford, IL, USA) at the Canterbury Health Laboratories 
(Christchurch, New Zealand). 
Histology and immunohistochemistry 
Fixed (neutral buffered formalin) kidney tissue was wax embedded and sections cut at 3µm.  
For histology, sections were stained with Masson’s Trichrome or periodic acid-Schiff’s (PAS) 
stain using conventional protocols. Cortical regions of interest were examined on an 
Olympus Provis AX70 microscope and photographed with a Spot digital camera (Olympus 
Corp., Tokyo, Japan).  For immunohistochemistry, sections were dewaxed and rehydrated.  
Antigen retrieval was generated by microwaving in 10 mmol/l citrate buffer, pH 6.0 for 10 
mins.  Endogenous peroxidase activity was blocked with 3% hydrogen peroxide in 
phosphate-buffered saline (PBS).  After preincubation in 1% BSA (Sigma Aldrich, St Louis, 
MO, USA) in phosphate-buffered saline (PBS)  to block non-specific binding, sections were 
incubated with the selected antibody.  Antibodies used were against: connective tissue 
growth factor (CTGF), β-catenin, transforming growth factor β1 (TGFβ1) (all Santa Cruz 
Biotechnology, Dallas, TX, USA), α-smooth muscle actin (αSMA) (Sigma Aldrich, St Louis, MO, 
USA), collagen 3 (Rocklands Immunochemicals, Limerick, PA, USA) and AQP2 (Chiron 
Mimetopes, Melbourne, Australia).13  Labelling of the tissue was visualised using a 
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horseradish peroxidise-coupled secondary immunoglobulin (IgG-HRP, DAKO, Glostrup, 
Denmark), followed by incubation with diaminobenzidine (Sigma-Fast tablets, Sigma Aldrich, 
St Louis, MO, USA) and the tissue was counterstained with Erhlich’s haematoxylin.  After 
dehydration and clearing, the sections were mounted in DPX.   Negative controls were 
carried out either by omitting the primary antibodies or by using appropriate blocking 
peptides, and positive controls used appropriately chosen tissues.    
 For quantitative determination of collagen 3, immunostained sections from each rat 
were examined microscopically and a series of at least 25 images was collected into 
Photoshop®, during an excursion across the section, either through the cortex or outer 
medulla.  Changes in the measurement of changes in the amount of collagen 3 present 
could be distorted by  recording the presence of collagen surrounding blood vessels.  Thus, if 
a blood vessel came into the field of view the field was adjusted to the right or left to 
remove it and scanning continued.   These images were analysed using a mask of 100 
microns square, and a subroutine in ImageJ (IHC Profiler), and the area of DAB staining 
expressed as a percentage of the field. A similar approach was used to quantify 
myofibroblasts, but in this case the number of α-SMA positive cells was counted, and 
expressed as the number in each 100 µ square area.  
Quantitative RT-PCR 
The medulla and cortex were separated, homogenised in Trizol® (Invitrogen, Life 
Technologies, ThermoFisher Scientific, Waltham, MA, USA) and the RNA extracted by 
precipitation.  The RNA was reverse transcribed using a Supercript III First Strand Synthesis 
kit (Invitrogen, Life Technologies, ThermoFisher Scientific, Waltham, MA, USA) with random 
hexamers.  The resulting cDNA was reacted with SYBR® Premix Ex TaqTM Rox Plus kit (Takara 
Bio, Shiga, Japan) in the CFX Connect Real Time PCR system (BioRad, Berkeley, CA, USA). The 
housekeeping gene β-actin  was used.  Relative quantification was carried out using ∆Cts.  
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Statistics 
All quantitative results are expressed as mean ± SEM.  Differences among the means of 
multiple parameters were analysed by one or two way analysis of variance (ANOVA) and 
Student’s t-test.  After ANOVA, the Bonferroni’s post hoc test was performed to compare 
each of the groups to the others (Prism 5 software, San Diego, CA, USA).  Values of P<0.05 




Rats fed lithium had established NDI by the end of 4 weeks of treatment.   At this time their 
urine output was 429 ± 5 µl/min/kg,  significantly more (P<0.001) than the control group 
which was 74 ± 6 µl/kg/min (Table 2).  Lithium treated rats  remained polyuric over the next 
5 months. with almost no change in urine production (413 ± 67 µl/min/kg). The animals 
given amiloride, however, had a greatly reduced  urine volume (128 ± 19 µl/min/kg. The 
changes in urine volume were associated with corresponding changes in urine osmolality 
(control group, 2007 ± 51 mOsm/kg water; lithium group, 199 ± 14 mOsm/kg water 
(P<0.001); amiloride group 590 ± 80 mOsm kg/water (P<0.001).  These results are consistent 
with partial correction of the lithium-induced NDI with amiloride when compared to the 
control animals (Table 2).  Plasma lithium concentrations in both experimental groups were 
maintained at the high end of the therapeutic dosage recommended for humans.  At 6 
months, lithium concentration in the lithium group was 1.1 ± 0.1 mmol/l and in the 
amiloride group 1.2 ± 0.1 mmol/l.  Plasma electrolytes, plasma osmotic pressure and renal 
function were comparable in all 3 groups (Table 2), although all rats given lithium showed a 
significant increase in sodium output   as the rats used the salt blocks provided.  Sodium 
excretion  was less in the amiloride group although it remained significantly higher than in 
the control group (Table 2).  There was a small but significant increase in urinary protein in 
the lithium group. 
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 Consonant with the measured physiological changes in the urinary concentrating 
ability, the water channel, aquaporin 2 (AQP2) showed related changes.  AQP2 was present 
throughout the renal collecting ducts of the control group (Fig. 1A,E,I), but was sparse in the 
experimental groups after 1 month of lithium treatment (Fig. 1B,F,J).  The lithium group still 
showed low levels of AQP2 after a further 5 months on lithium (Fig. 1C,G,K).  However the 
partial recovery of the concentrating ability shown by the amiloride group at 6 months was 
reflected in the increased presence of AQP2 (Fig.1D,H,L), albeit mainly with an intracellular 
distribution, and more prominently in the renal medulla.  It is notable that the cystic 
dilatations of the collecting ducts, in the outer cortex, remain without 
immunohistochemically detectable levels of AQP2 in this group. 
 
Effect of amiloride on the morphological changes induced by lithium 
Fig. 2 illustrates the morphological changes in the renal cortex resulting from lithium 
treatment, and the effect of co-administration of amiloride.  Compared with the control 
group (Fig. 2A,B) after 1 month of lithium exposure, morphological changes have become 
apparent in the renal cortex (Fig. 2C,D).  The collecting ducts are dilated and appear  to be 
either cyst-like, with the epithelium stretched thinly over the enlarged lumen, or to be 
composed of many greatly enlarged cells, many with prominent nuclei, and some cells 
appearing to be binucleate.  
 With an additional  5 months of lithium exposure, these changes had progressed 
further. The cortical cystic dilatations were increased in size, and many were surrounded by 
interstitial cells (Fig. 2F).  There appeared to be an accumulation of extracellular collagen 
around the tubules, some of which were compressed and appeared to be non-functional 
(Fig. 2E).  Additionally, there were subtle changes in glomerular morphology (Fig. 3A-C).  
Many glomeruli showed evidence of a focal glomerulosclerosis, of 142 glomeruli examined 
from three animals, 36 showed evidence of sclerosis,   while 12 appeared to have an 
attachment to the capsule wall. However, in the animals given amiloride and lithium, only 
13 out of 105 glomeruli showed evidence of sclerosis (Fig. 3C). There was no visible evidence 
of glomerular damage in either the control animals or those sacrificed after one month of 
lithium exposure. The observed changes in the glomeruli were associated with a small  
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increase in proteinuria (Table 2).  In spite of these observed histological changes, there was 
no deterioration in renal function as measured by plasma creatinine (Table 2). 
 In marked contrast to the progressive changes shown by the kidneys of the lithium 
group, kidneys of rats given amiloride (together with lithium) for 5 months of the 
experimental period, showed little if any difference in morphology from the appearance of 
those with only 1 month of lithium treatment (Fig. 2E,F).  Although the cortical collecting 
ducts were dilated, there were few  associated accumulations of interstitial cells, and no 
extensive peritubular collagen deposition.   
 
Effect of amiloride on the profibrotic changes induced by lithium 
                Localisation of αSMA identifies the smooth muscle fibres enveloping blood vessels 
and also myofibroblasts, which accumulate in regions of cellular injury and are responsible 
for the deposition of collagen. Fig. 4A showed that apart from its presence in blood vessels, 
αSMA is absent from the cortex of control rats.  At 1 month (Fig. 4B) myofibroblasts (arrows) 
can be identified in small numbers, as thin structures closely adpressed to basement 
membranes of distal tubules and collecting ducts.  By 6 months of lithium treatment (Fig. 
4C) myofibroblasts were present in considerable numbers in the cortex, mainly adjacent to 
the cystic dilatations of the collecting ducts.  In marked contrast, the kidneys of the 
amiloride group (Fig. 4D). revealed an almost total absence of fibroblasts.   Measurement of 
the number of myofibroblasts present in the renal cortex, calculated as the mean of 100 
random samples, found no significant difference between the abundance of myofibroblasts 
in the control animals (1.2 ± 0.35/100 µ2), those treated with lithium for one month (2.09 ± 
0.17/100 µ2) and those given lithium plus amiloride for six months (0.78 ± 0.19/100 µ2).   
There was however a significant difference in the abundance of myofibroblasts in the renal 
cortex of animals given lithium alone for six months (5.44 ± 0.53/100 µ2, P<0.0001). The high 
standard error in this measurement reflects the fact that the distribution of myofibroblasts 
in this tissue was irregular, clusters being located adjacent to the collecting ducts. 
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                  These results were matched by the amount and distribution of collagen 3, which 
in control rats occured only in the intima of blood vessels (Fig. 5A), and only sparsely in the 
interstitium after 1 month of lithium treatment (Fig. 5B).  After 6 months of lithium 
exposure there was an extensive network of collagen fibres in the vicinity of the dilated 
collecting ducts (Fig. 5C).  However, in the amiloride group, the abundance and distribution 
of collagen 3 was similar to that of the animals exposed to lithium for 1 month (Fig. 5D).   
Measurement of the extent of collagen (measurement as the percentage of the area of the 
100 µ2 sampling mask)  showed little difference between the controls (0.93 ± 0.03), the one 
month lithium group (0.99 ± 0.08) and the group given amiloride (1.07 ± 0.06), while the 6 
month lithium group had substantially more collagen in the renal cortex (3.21 ± 0.04, 
P<0.001).          
                 A key element in the progression of fibrosis is widely held to be CTGF, which may 
be modulated via TGFβ1 or in some cases independently.  The effect of lithium on CTGF 
distribution in the renal cortex is shown in Fig. 6A-D).  CTGF is confined to the basolateral 
membranes of distal tubules and collecting ducts and there appears to be little change in 
the distribution or abundance in all 4 groups.                       
On the other hand, the picture of TGFβ localisation, as shown by 
immunohistochemistry (Fig. 7) presented unexpected data.  TGFβ1 appears to be absent in 
the control renal cortex, and only barely appears after one month of lithium treatment (Fig. 
7B), where it was confined to the Bowman’s space of a few glomeruli.  After six months 
exposure to lithium, TGFβ1 was distributed throughout the interstitial spaces and in the 
glomerular capillaries (Fig. 7C).   In marked contrast, in those animals given amiloride in 
addition to lithium, TGFβ1 was weakly distributed intracellularly in the distal tubules, but 
absent extracellularly (Fig. 7D).                 
Localisation of β-catenin in the lithium group appears to be increased in the 
distal tubules and collecting ducts (Fig. 8C). β-catenin expression was also enhanced in the 
amiloride group (Fig. 8D) when compared to the control rats (Fig. 8A).  There was however 
some suggestion of a lowered intensity of β-catenin expression lining the basolateral 
membranes of the epithelial cells in the amiloride treated animals (Fig. 8D) compared with 
the lithium group. 
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mRNA expression of collagen 3, CTGF and TGFβ1 
                     Collagen 3 mRNA expression showed a 2.80 ± 0.22 fold increase (P<0.001) in the 
cortex of the kidneys from lithium treated rats compared to controls.  Amiloride 
administration resulted in a down regulation of collagen 3 mRNA (1.6 ± 0.31, P<0.01, cortex) 
to values similar to that of the control animals (Fig. 9).  TGFβ1 mRNA expression 
demonstrated a 3.4 ± 0.61 fold increase (P<0.01) in the cortex with lithium treatment only 
whereas co-treatment with amiloride reduced TGFβ1 mRNA to values similar to control 
values (1.9 ± 0.67, P<0.01 compared with lithium only).  A similar pattern was seen with 
CTGF mRNA expression with a 3.0 ± 0.4 fold increase (P<0.01) in the cortex of lithium 
treated animals. Amiloride co-treatment resulted in CTGF mRNA values being similar to that 
seen in the control group (1.8 ± 0.55, NS).  AQP2 mRNA in the cortex was clearly down-




This study has demonstrated that administration of amiloride to rats that had already 
developed NDI, not only partially restored the concentrating ability of the kidney, but also 
and more importantly, limited the progressive development of cortical fibrosis resulting 
from the chronic lithium exposure.  In an earlier study, rats showed evidence of renal 
interstitial fibrosis after 4 weeks exposure to lithium, which had become extensive after 6 
months of continued lithium.4  In the present study, attempts to demonstrate quantitatively 
the development of fibrosis at one month were  not successful.   This was due to the fact 
that deposition of collagen was confined to foci, largely around collecting ducts, so that 
random measurement of its abundance gave data that was little different from the controls, 
although the difference was clearly obvious on microscopic examination (Fig. 5 A,B), The 
changes reported earlier were reproduced in this study but a key additional finding reported 
here was that amiloride, commenced after 4 weeks of lithium treatment, effectively 
prevented the further progression of cortical fibrosis as well as a sustained partial reversal 
of the lithium-induced NDI. 
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            Long term exposure to lithium has been associated with the development of a 
chronic focal interstitial fibrosis, tubular atrophy and focal glomerulosclerosis,2 that may 
progress to end stage renal disease.3  The pattern of histological injury in this model reflects 
the changes evident in long-term lithium exposure in humans. Markowitz and colleagues 
documented a chronic tubulointerstitial nephropathy with focal glomerulosclerosis in a 
series of 24 patients with biopsy-proven lithium toxicity.3  In the human biopsies there was a 
chronic interstitial fibrosis predominately involving the distal and collecting tubules.  They 
also demonstrated the presence of a focal segmental glomerulosclerosis in 50% of the 
biopsies.  In the present study, we found a similar pattern of focal glomerulosclerosis, 
present in approximately one third of glomeruli observed in each of the lithium-fed animals, 
which was associated with mild proteinuria in these rats. Of considerable interest was the 
observation that chronic amiloride administration, started 1 month after the establishment 
of lithium-induced NDI, limited the development of focal glomerulosclerosis, along with an 
associated reduction in proteinuria.  This study was not designed to investigate glomerular 
changes related to lithium exposure, so further studies are proposed to explore this 
intriguing observation.  The prevention of the progression of lithium-induced fibrosis, by the 
co-administration of amiloride, was associated with a reduced expression of the pro-fibrotic 
cytokine CTGF along with decreased myofibroblast activity as measured by αSMA staining 
and decreased collagen 3 deposition.  Amiloride, by reducing the cellular uptake of lithium, 
is presumably altering the intracellular regulatory pathways associated with the 
development of fibrosis. 
         Earlier animal models demonstrated that lithium inhibits intracellular adenylate cyclase 
activity leading to lower intracellular concentrations of cAMP.14  Duncan and co-workers15 
reported that cAMP, both in vitro and in vivo, inhibited TGFβ-mediated collagen synthesis as 
well as having an impact on the CTGF mediated pathway.  Activation of adenylate cyclase 
also led to the inhibition of TGFβ and CTGF mediated fibrotic pathways.15  Based on these 
findings it is postulated that lithium inhibition of intracellular adenylate cyclase leads to the 
disruption of the downstream signalling pathways, either directly via cAMP, or indirectly by 
loss of activation of cAMP response element binding protein (CREB) which normally down-
regulates CTGF gene expression.  Hence lithium can lead to an upregulation of CTGF that 
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may or may not be associated with alterations in TGFβ1 expression, that is then associated 
with an increased fibrosis as demonstrated in this study. 
          Lithium also increases the phosphorylated (inactive) form of GSK3β, and lithium-
induced fibrosis may be mediated in part, via inhibition of GSK3β.8,16 GSK3β modulates the 
actions of adenylate cyclase so inhibition of GSK3β may lead to a decrease in adenylate 
cyclase activity contributing to the profibrotic changes evident with lithium therapy.  The 
lithium-induced inhibition of GSK3β may also be important in the upregulation of the 
profibrotic processes. In addition, GSK3β constitutively phosphorylates β-catenin, an 
important transcription factor involved in epithelial-mesenchymal transition (EMT), a 
phenomenon proposed to be crucial in fibrogenesis.17 β-catenin expression, as a 
downstream marker of GSK3β inhibition (Fig. 8) was increased with lithium treatment and 
partially reduced with the co-administration of amiloride.  Clearly, these findings will need 
to be sustained with further experiments. 
 
           Chronic lithium therapy not only produces a chronic interstitial fibrosis.  There are a 
number of published studies demonstrating that lithium induces hyperplastic changes in the 
medullary collecting ducts, along with dilated late distal tubule and connecting tubule 
segments with characteristic distal tubule dilatation and microcyst function.  These changes 
are evident after only 3-4 weeks exposure to lithium.4,18-20  The degree of distal tubule 
dilatation and other changes of interstitial nephropathy tends to progress with duration of 
lithium exposure.4,18,19  Of interest in this study was the finding that, although the co-
administration of amiloride prevented the progression of the interstitial fibrosis, there was 
no alteration of the morphological changes induced by lithium.  The mechanisms by which 
lithium induces the cellular changes are not known.  In a previous paper4 Walker et al. 
suggested that the cortical changes induced by lithium exposure might be due to crosstalk 
resulting from lithium entry into proximal tubular cells resulting in the release of cytokines 
causing a fibrotic response in the distal tubules. Marouf et al. 21 have recently presented 
evidence that interstitial fibrosis may be driven by Wnt signalling from the proximal tubules.  
In the lithium-treated rat, lithium concentration in the proximal tubule is at a concentration 
near 1 mmol/litre.   Alsady et al.22, in discussing lithium handling in the kidney, point out 
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that, as has been known for many years, about 70% of filtered lithium is reabsorbed in the 
proximal tubule.  Much of this reabsorption must be transcellular.  The lithium-transporting 
pathway is not known, but is thought to be the sodium–hydrogen exchanger NHE3, which 
can be blocked by amiloride at concentrations of >50-100 µmol23  It is possible therefore 
that lithium could enter the proximal tubular cells via NHE3 and leave through the 
basolateral action of NHE1.  Although NHE3 has a low affinity for lithium, it may be sufficient 
to disrupt cellular metabolism and lead to a release of Wnt1 ligands, in turn activating 
interstitial fibrosis.  Clearly further studies are required to investigate how these cellular 
changes occur and to see if administration of amiloride at the onset of lithium treatment 
prevents the development of the dilated cystic tubules and cellular abnormalities.   
             This study has demonstrated that the progressive development of chronic interstitial 
fibrosis induced by long term lithium exposure is significantly suppressed by the addition of 
amiloride 4 weeks after the commencement of lithium therapy.  This was associated with 
the downregulation of the key profibrotic cytokine CTGF, which, may in part, be mediated 
by lithium-induced changes in GSK3β activity and/or adenyl cyclase.  This may have 
significant clinical interest in limiting progression of lithium-induced renal fibrosis. 
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                   Control   1 month Lithium          6 months Lithium   Lithium + Amiloride 
       
       
       
Figure 1. Representative regions of rat kidneys showing the localization of AQP2.   Control  (A,E,I); after 1 month on a lithium diet (B,F,J);  after 
6 months on a lithium diet (C,G,K);  after 1 month of lithium exposure followed by 5 months on lithium with co-administration of amiloride 
(D,H,L).  Top row,  cortex; middle row, outer medulla; bottom row, inner medulla.  DAB staining shows localization of AQP2 on the apical 
membranes of the collecting ducts. Magnification x 400. 
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         Control        1 month Lithium         6 months Lithium         Lithium + amiloride 
     
    
Figure 2. Representative regions of the cortex of rat kidneys stained with Masson’s Trichrome. Control  (A,B); after 1 month on a lithium diet 
(C,D);  after 6 months on a lithium diet (E,F); after 1 month on a lithium diet followed by 5 months on lithium with co-administration of 




















Figure 3.  Representative glomeruli from  (A) control;  (B) after 6 months on a lithium diet - 
focal glomerulosclerosis ;  (C)  a glomerulus with adhesions to the capsular wall. 
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Figure 4. Representative regions of the cortex of rat kidneys showing localization of αSMA. Control  (A), after 1 
month on a lithium diet (B), after 6 months on a lithium diet (C), 1 month of lithium exposure followed by 5 
months on lithium with co-administration of amiloride (D).   In A: arrow indicates smooth muscle of arteriole; 
B,C: arrows point to myofibroblasts beneath the epithelium of the collecting duct; D: only a few 
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Figure 5. Representative regions of the cortex of rat kidneys showing localization of collagen 
3. Control  (A) where arrows indicate collagen 3 surrounding a small arteriole; (B) after 1 
month on a lithium diet collagen 3 is present around collecing ducts (arrows );  (C)  after 6 
months on a lithium diet collagen 3 deposition is more extensive;   (D) after 1 month of 
lithium exposure followed by 5 months on lithium with co-administration of amiloride 
shows that collagen 3 is still present around collecting ducts but is comparable in extent to 
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Figure 6. Representative regions of the cortex of rat kidneys showing localization of CTGF. 
Control  (A);  after 1 month on a lithium diet (B) after 6 months on a lithium diet (C);  after  1 
month of lithium exposure followed by 5 months on lithium with co-administration of 
amiloride (D).   CTGF is confined to the basolateral membranes of the thick ascending limb 
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Figure 7. Representative regions of the cortex of rat kidneys showing localization of  TGFβ1.  
Control  (A); after 1 month on a lithium diet (B) – arrow points to glomerular distribution of 
TGFβ1;  after 6 months on a lithium diet (C); after 1 month of lithium exposure followed by 5 
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Figure 8.  Representative regions of the cortex of rat kidneys showing localization of β-
catenin. Control  (A);  after 1 month on a lithium diet (B);  after 6 months on a lithium diet 
(C); after 1 month of lithium exposure followed by 5 months on lithium with co-















Figure 9.  mRNA expression (2∆∆CT) of collagen 3, TGFβ1, CTGF and AQP2 from extracts 
from the cortex  from the  kidneys of rats. Experimental conditions were control, after 6 
months on a lithium diet, 1 month of lithium exposure followed by 5 months on lithium with 
co-administration of amiloride  ***P<0.001 and **P<0.01 compared to controls; ##P<0.01 
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Table 1. Forward and reverse primer sequences for TGFβ1, CTGF, collagen 3, AQP2 and β-actin for 
Rattus norvegicus 
  
 Gene                                                                 Primer 
Transforming                 Forward : AAGGCACATCCTTGGACGAAGGTC (24 b) 
Growth factor                Reverse : TGTGCACAAGCTTCCAGTGGTG  
    (TGFβ1)                   (reverse complement: CACCACTGGAAGCTTGTGCACA) (22 b) 
 
Connective                  Forward : AGCGCTGACATTCTGATTCCAGTG (24b) 
Tissue growth             Reverse :  ACTTGCCACAAGCTGTCCAGTC  
 Factor (CTGF)             (reverse complement: GACTGGACAGCTTGTGGCAAGT) (22 b) 
 
Collagen 3                    Forward : TGCCTACATGGATCAGGCCAATG (23 b) 
                                       Reverse :  TGCTCCATTCACCAGTGTGTTTAG  
                                 (reverse complement: CTAAACACACTGGTGAATGGAGCA) (24 b) 
 
Aquaporin 2                 Forward : CTGCCCTCTCCATTGGTTTCTC  (22 b) 
      AQP2                       Reverse :  TGGAGCAACCGGTGAAATAGATCC  
      (reverse complement: GGATCTATTTCACCGGTTGCTCCA) (24 b) 
 
Β-actin                           Forward : ACCCGCGAGTACAACCTTCTTG (22 b) 
                                        Reverse : TATCGTCATCCATGGCGAACTGG  
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Table 2.  Physiological parameters of rats maintained on a lithium diet for 1 and 6 months, 
and on lithium + amiloride for 6 months. 






     
Body weight (g) 428 ± 14A 304 ± 2*** 414 ± 13*** 442 ± 10*** 
Plasma composition     
Na+ (mmol/l) 134 ± 1 145 ± 5 138 ± 1 138 ± 1 
K+  (mmol/l) 5.6 ± 0.1 5.3 ± 0.1 5.6 ± 0.1 5.5 ± 0.1 
Li+ (mmol/l) 0 1.4 ± 0.1 1.1 ± 0.1 1.2 ± 0.1 
Cl- (mmol/l) 97 ± 2 100 ± 3 96 ± 2 98 ± 2 
Osmotic pressure 
(mOsm/kg water) 
289 ± 1 295 ± 2 291 ± 1 290 ± 1 
Urea  (mM/l) 6.9 ± 0.8 6.5 ± 0.8 5.9 ± 0.5 5.8 ± 0.5 
Creatinine  (µmol/l) 108 ± 17 120 ± 15 155 ± 22 110 ± 20 
Amiloride  (mmol/l) ND ND ND 0.65 ± 0.07 
Urine composition     
Urine output 
(µl/min/kg) 
74 ± 6 429 ± 30*** 413 ± 67*** 128 ± 19**### 
Na+ (mmol/l) 39 ± 6 18 ± 2** 14 ± 4*** 22 ± 4*## 
K+  (mmol/l) 185 ± 18 15 ± 1*** 11 ± 3*** 30 ± 15 
Li+ (mmol/l) 0 3.0 ± 0.3 2.6 ± 0.8 4.2 ± 0.3 
Osmotic pressure 
(mOsm/kg water) 
2007 ± 51 178 ± 10*** 199 ± 14*** 590 ± 80### 
Protein (mg/hr/100g) 0.4 ± 0.2 3.2 ± 0.5*** 2.1 ± 0.1*** 0.2 ± 0.3### 
     
A = weight at 1 month after commencement of experiment, 6 month weight = 600 ± 19 g 
Values are means ± SEM. *** P < 0.001/ ** P < 0.001 / * P < 0.05  lithium treated  and 
amiloride rats compared to control values.   ###P < 0.001/ ##P < 0.001/ #P < 0.05 lithium 
treated rats compared to the rats administered lithium and amiloride. One-way ANOVA, 
Bonferroni’s post-hoc test was used to compare the groups lithium vs lithium + amiloride 
and each of these against the controls. n = 7 (lithium), n = 6 (control and lithium + amiloride 
group).  ND = not determined. 
 
 
